Commentary
While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, NAFLD) or NASH) are nowadays the leading causes of hepatic fibrosis worldwide. In this review, F. Tacke et al. (Charité University Medicine, Berlin, Germany) discuss recent advances in antifibrotic prevention and therapy.
For the authors, “tackling NAFLD-associated fibrosis from different directions by combinatorial drug treatment and effective lifestyle changes hold the greatest prospects.”
Previous Post
NASH: a complex disease
Next Post
Increased portal pressure in non-cirrhotic NAFLD: a review